The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women

Inclusion Criteria: * Female with age range 21 to 44 years * Subjects who are seeking permanent contraception * Subjects with body weight within range of 40 - 136 kilograms (90-300 pounds) * Subjects willing to accept the risk of pregnancy occurring while relying solely on the ESS505 as contraception * Subjects for whom medical history and physical examination indicates bilateral viable and patent fallopian tubes * Subjects who are able to comply with the protocol required follow-up visits (e.g., 3 month clinic visit, and the 12-month telephone interview) * Subjects who provide written informed consent prior to enrolment * Subjects who have sufficient mental capability to provide clinically relevant and reliable feedback regarding her experience wearing the device * Subjects agrees that her anonymised personal data will be made available to Study sponsor, requisite regional and international regulatory bodies * Subjects for whom there are no contraindications for use as described in the ESS505 Instructions for Use (IFU) Exclusion Criteria: * Subjects with known proximal tubal occlusion in either fallopian tube * Subjects who have undergone fallopian tube sterilization procedure * Subjects diagnosed with unicornuate uterus * Subjects diagnosed with endometrial or myometrial pathology which may prevent fallopian tube ostia assessment * Subjects scheduled to undergo concomitant intrauterine procedures at the time of ESS505 placement; IUD removal is not considered a concomitant procedure * Subjects suspected of being or confirmed pregnant * Subjects post-partum or has undergone pregnancy termination ≤6 weeks of scheduled ESS505 placement * Subjects diagnosed with active upper or lower pelvic infection * Subjects for whom there are one or more contraindications for use as described in the ESS505 IFU * Subjects have positive pre-procedure pregnancy test